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The comprehensive report in this issue by Ranger et al.
(1) is a landmark contribution for several reasons: first, it
identifies an important regulatory agent that functions in
 
several diverse mesenchymal pathways; second, it shows that
transcription factors that affect differentiation pathways in
adults are not necessarily prominent in embryonic events;
third, it documents that alert and inquisitive minds are most
effective when their field of vision is not restricted to the
narrow limit of their specialized fields; and finally, it dem-
onstrates that collegial and scholarly networks are impor-
tant in scientific inquiry. In the context of this last point, it
is important to point out that although the physician–basic
scientist phenotype is being squeezed by fiscal and organi-
zational constraints and is, thus, endangered, the physician-
scientists are well positioned as bridging components and
 
are uniquely contributory to the progress of scientific in-
 
quiry. As an unusual human interest aside, a behind-the-scenes
situation developed in which the molecular immunologist
daughter went to her orthopedic surgeon father to help un-
ravel the key features of an experimental system.
The primary focus of these studies is the nuclear factor of
activated T cells (NFAT) family of transcription factors that
 
are regulatory components in T lymphocyte activation in
adults (2, 3). Interestingly, one member of this family, NFATc,
is active in the morphogenesis of cardiac valves and septum (4,
5), indicating that other members of the NFAT family could
be regulators of other mesenchymal tissues. In the 1990s, one
powerful way to study a family of regulatory factors is to
“knock out” each gene of that family and to study the devel-
opmental and physiological consequences. Laurie H. Glim-
cher’s laboratory and others used this strategy (4-10) and, as
might be expected, observed that the immune system of
the mice was affected. Importantly, new insight into the
control of the genesis of a specific class of immune cells was
obtained that may have implications for organ transplanta-
tion or immune deficiency diseases. In the tedious and of-
ten unrewarding process of raising, back-crossing, and breed-
ing these knockout mice, the researchers in Glimcher’s lab
noticed that the older, breeding, NFATp-deficient female
mice had distinctive limps and eventually developed severe
ambulation problems. For a laboratory focusing on the de-
tails of immune regulation, this side-observation was bother-
some but certainly not profound. This ambulation difficulty
may have led to naught had Laurie Glimcher, an established
T cell molecular biologist (6, 7, 11–14), not been the daugh-
ter of Melvin J. Glimcher, a prominent orthopedic surgeon
and scientist who has worked on aspects of bone formation
and biomineralization for over 40 years (15–19). This for-
tuitous meeting of two genetically related minds led to an
in-depth analysis of the NFATp knockouts as they relate to
cartilage and bone turnover and differentiation from adult
cells. Upon review of the histological slides of various joints
 
of NFATp-deficient adult mice by the Glimchers, the
members of their laboratories, and other orthopedic col-
leagues in Boston, they concluded that the ambulatory prob-
lem arose from an overabundance of cartilage in the joint.
Melvin Glimcher hypothesized that this exuberant cartilage
growth arose as a result of uncontrolled mesenchymal stem
cell (MSC) differentiation and suggested that they contact
our laboratory. We provided human (20–22) and mouse
(23, 24) MSC preparations in various stages of differentia-
tion to be used for the analysis of NFATp expression. These
collegial networks and scholarly interactions led to the
identification of NFATp as the first repressing transcription
factor regulating adult MSC differentiation into the chondro-
genic pathway. Had Laurie Glimcher’s lab not been diligent
in its pursuit of the cause of the limping in the knockout
mice and had these multiinstitutional, multigenerational,
and scholarly networks not been available and active, it is
possible that this important observation would have been
missed.
This late onset, adult cartilage overexpression in the
NFATp knockouts reinforces the thesis that this and other
laboratories put forth many years ago (25): namely, that a
genetically regulated developmental program that controls
embryonic events does not cease at birth but continues
throughout life, albeit at much slower rates. Thus, postfetal
changes in cells, tissues, and organs occur throughout the
entire life span of an organism, and are small and occur rel-
atively slowly compared with embryologic events. The fact
that 20-yr-old, 50-yr-old, and 80-yr-old organisms are dif-
ferent in tissue morphologies and functions implies that the
sequential changes are programmatically controlled. The
fact that newborn and neonatal NFATp knockout mice
have totally normal skeletal and cartilage structures indi-
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cates that NFATp is not a prominent control element dur-
ing the preceding developmental period. Thus, the report
in this issue by Ranger et al. (1) establishes not only that
specific transcription factors tightly control the morphology
and function of certain tissues, but also that the regulatory
program itself changes with postnatal age, such that NFATp
plays a dominant role in adult MSC activities even though
it has no apparent influence in embryonic or neonatal mes-
enchymal events. Thus, transcription factors, in this case
one with repressor activity, join the list of molecules that
are cassetted into action during distinctive transitions that
occur in adult life. For example, the adult skeletal muscle
myosin isoform is inserted into functioning contraction ar-
rays long after the embryonic and neonatal isoforms have
sequentially appeared (26, 27). Likewise, the posttransla-
tional fabrication of the chondroitin sulfate chains of the
cartilage proteoglycan, aggrecan, continually changes through-
out life and probably accounts for the decreased resiliency of
cartilage and, thus, increased susceptibility to damage with
age (25, 28). In this latter case, cartilage doesn’t “age,” but
rather the molecules that are slowly replacing their prede-
cessors (i.e., turnover) are themselves different and less able
to effectively structure water, resulting in a progression
leading to mechanically compromised tissue.
The factors that regulate turnover and repair in adult tis-
sues may be different from those observed during develop-
ment. That these events are under genetic control is obvi-
ous from observing families that have problems with joint
cartilage with age compared with those that rarely have
problems. Some of the molecules responsible for these her-
itable characteristics may be adult-dominant transcription fac-
tors like NFATp. In sum, developmental changes continue
throughout the life span of the organism, and aging, by it-
self, is the readout of a slower adult genetic program. Thus,
it is clear that the medical complexity of aging will be mul-
tifactorial and that cell- and organ-specific cures will re-
quire interfaces at many loci.
In retrospect, it also seems logical that the NFAT family
of transcription factors would target MSCs, their individual
differentiation pathways, and/or their differentiated prog-
eny. Several years ago, we proposed (21) the existence of
the multipathway scheme referred to as the Mesengenic
Lineage in which adult MSCs could differentiate down a
number of phenotypic pathways (Fig. 1). Both hematopoi-
etic stem cells and MSCs are derived embryologically from a
common mesodermal progenitor (29). Now it seems that
the NFAT family of transcription factors, which has been
shown to affect components of hematopoietic pathways,
might also influence the other mesenchymally derived tis-
sues, such as cardiac and skeletal muscle, adipose tissue, and
now, cartilage. Whether NFATp only targets MSCs for all
of these mesenchymal tissues is still an open question; in
contrast, the report by Ranger et al. (1) clearly establishes
its effect on the adult chondrogenic pathway. The issue
now is to translate this molecular discovery into treatment
protocols that address aging-related cartilage failure.
Figure 1. The mesengenic
process. MSCs have the potential
to differentiate into a variety of
mesenchymal tissues, such as
bone, cartilage, tendon, muscle,
marrow, fat, and dermis. Prolif-
erating MSCs enter a lineage af-
ter their commitment to that
particular pathway. The com-
mitment event involves the ac-
tion of specific growth factors
and/or cytokines, as does the
next phase in which the lineage-
committed cells progress through
several transitory stages in the
lineage progression process. Ter-
minal differentiation involves the
cessation of proliferation and the
massive biosynthesis of tissue-
specific products, usually highly
site-specific extracellular matrix.
Finally, these differentiated cells
go through a maturation stage in
which they acquire an ability to
function in aspects of tissue ho-
meostasis as opposed to high lev-
els of synthetic activity. All of
these end stage–differentiated
cells have fixed half-lives and can
be expected to expire; these cells
are replaced by newly differenti-
ated cells arising from the con-
tinuous transition down the lin-
eage pathway (reproduced from
reference 20). 
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